Professor Ananya Choudhury

Professor Choudhury is Chair and Honorary Consultant in Clinical Oncology. She joined The Christie in 2008 specialising in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. She is clinical lead for advanced radiotherapy, including the MRLinac project, and is co-Group Leader of The Translational Radiobiology Group within the Division of Cancer Sciences.

Professor Choudhury currently undertakes research which aims to optimise and personalise radiotherapy using new techniques or imaging technology to deliver high doses of radiotherapy while minimising side effects and predictive biomarkers to determine which patients benefit from different treatments.

Chair and Honorary Consultant

Professor Choudhury graduated from Trinity College, Cambridge, but undertook her Clinical Oncology training at the Yorkshire Deanery from 2000-2008. Between 2005 and 2007, she was a Cancer Research UK Clinical Training Research Fellow and she undertook her PhD at the University of Leeds and Princess Margaret Hospital in Toronto, Canada. For her PhD she studied the molecular epidemiology of DNA double strand break repair in bladder cancer and the use of systemic agents for enhanced chemosensitivity and radiosensitivity. She has a lead role in education and training for specialist registrars and clinical fellows.

Professor Choudhury is a member of a member of work stream 2 of the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group (CTRad) and of the NCRI Bladder Clinical Studies Group. She has also been a member of the NICE bladder cancer guideline development group. She is currently a member of the RCR Clinical Oncology Academic Committee. From 2017-2020, Professor Choudhury was Senior Editor for genito-urinary cancers for the International Journal of Radiation Oncology • Biology • Physics (The Red Journal), and since early 2021, is the Clinical Oncology Editor in Chief.